BETAGAN
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Jun 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BETAGAN is an ophthalmic solution approved in 1989 for treatment of glaucoma and ocular hypertension. It is a small-molecule beta-blocker administered as eye drops. The drug reduces intraocular pressure by decreasing aqueous humor production.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure, the brand team is likely small and focused on defensive positioning against generic and newer therapies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BETAGAN offers limited career growth potential given its mature lifecycle stage and approaching loss of exclusivity. Roles on this product typically involve defensive strategies, generic preparation, and market maintenance rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on BETAGAN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.